Introducing OptimersTM

04:30 EDT 13 Oct 2018 | BioNow

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the shortest time possible. We are now including as standard our proprietary automated Minimal Aptamer Fragment Identification (MAFI) process for the development of kinetically optimised aptamers in the same delivery time as our previous approach. These improved aptamers will be differentiated from the standard library aptamers as OptimersTM.OptimersTM can have multiple advantages, when compared to their precursor aptamer sequences, making kinetic optimisation an essential step in the development of the highest quality reagents against cellular, protein or small molecular targets.Data demonstrating kinetic improvements can be found at If you are interested in reducing future assay costs, improving performance of your assay, downstream processing or therapeutic activity, then OptimerTM development would be the better solution.If you are facing challenges that OptimersTM could address and are attracted by the benefits they offer, contact our team at where they will be available to answer any queries you have.

Original Article: Introducing OptimersTM


More From BioPortfolio on "Introducing OptimersTM"

Quick Search


Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...